Ramsay R E
Department of Neurology, University of Miami School of Medicine, Florida.
Neurology. 1994 Jun;44(6 Suppl 5):S23-30; discussion S31-2.
The challenges of treating patients with partial seizures soon will be met, in part, by a number of new additions (felbamate, gabapentin, lamotrigine) to existing treatment options. Gabapentin, has shown significant promise in the treatment of patients with refractory partial seizures and secondarily generalized tonic-clonic seizures. Three large, randomized, multicenter, double-blind, placebo-controlled, parallel-group clinical trials have established its efficacy and safety as add-on therapy in patients with refractory partial seizures. Gabapentin is well tolerated. Although adverse events occur in most patients receiving gabapentin as adjunctive therapy, they are transient and mild to moderate in severity. To date, serious adverse events have been rare. Long-term safety data are needed. The lack of drug interaction potential between gabapentin and traditional antiepileptic drugs also was confirmed in clinical trials.
治疗部分性癫痫患者所面临的挑战，将在一定程度上通过在现有治疗方案中新增多种药物（非氨酯、加巴喷丁、拉莫三嗪）来应对。加巴喷丁在治疗难治性部分性癫痫和继发性全身性强直阵挛性癫痫患者方面已显示出巨大前景。三项大型、随机、多中心、双盲、安慰剂对照、平行组临床试验已证实其作为难治性部分性癫痫患者附加疗法的有效性和安全性。加巴喷丁耐受性良好。虽然大多数接受加巴喷丁辅助治疗的患者会出现不良事件，但这些事件是短暂的，严重程度为轻至中度。迄今为止，严重不良事件很少见。还需要长期安全性数据。加巴喷丁与传统抗癫痫药物之间缺乏药物相互作用的可能性也在临床试验中得到了证实。
